2018-05-01·Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2区 · 医学

Pulse-echo ultrasound method for detection of post-menopausal women with osteoporotic BMD

2区 · 医学

Article

作者: Kröger, H ; Riekkinen, O ; Karjalainen, J P

INTRODUCTION:

We lack effective screening and diagnostics of osteoporosis at primary health care. In this study, a pulse-echo ultrasound (US) method is investigated for osteoporosis screening.

METHODS:

A total of 1091 Caucasian women (aged 50-80 years) were recruited for the study and measured with US in the tibia and radius. This method measures cortical thickness and provides an estimate of bone mineral density (BMD) and density index (DI). BMD assessment of the hip was available for 988 women. A total of 888 women had one or more risk factors for osteoporosis (OP _susp ), and 100 women were classified healthy. Previously determined thresholds for the DI were evaluated for assessment of efficacy of the technique to detect hip BMD at osteoporotic range (T-score at or below - 2.5).

RESULTS:

In the OP _susp group, the application of thresholds for the DI showed that approximately 32% of the subjects would require an additional DXA measurement. The multi-site ultrasound (US) measurement-based DI showed 93.7% sensitivity and 81.6% specificity, whereas the corresponding values for single-site US measurement-based DI were 84.7 and 82.0%, respectively. The ultrasound measurements showed a high negative predictive value 97.7 to 99.2% in every age decade examined (ages 50-59, 60-69, 70-79 years).

CONCLUSIONS:

The study data demonstrate that a strategy of combining ultrasound measurement with added DXA measurements in cases with intermediate ultrasound results (about 30%) can be useful for identifying subjects at risk for a low bone mineral density in the osteoporotic range.

2017-01-01·Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2区 · 医学

Prediction of hip osteoporosis by DXA using a novel pulse-echo ultrasound device

2区 · 医学

Article

作者: Riekkinen, O ; Schousboe, J T ; Karjalainen, J

INTRODUCTION:

To estimate how well a pulse-echo ultrasound device discriminates those who have from those who do not have hip osteoporosis (femoral neck bone mineral density [BMD] or total hip BMD T-score ≤ -2.5), and to estimate the association of pulse-echo ultrasound measures with prevalent (radiographically confirmed) clinical fractures.

METHODS:

Five hundred fifty-five post-menopausal women age 50 to 89 had femoral neck and total hip BMD measured by dual-energy x-ray absorptiometry (DXA), and pulse-echo ultrasound measures of distal radius, proximal tibia, distal tibia cortical thickness, and multi- and single-site density indices (DI). Using previously published threshold ultrasound values, we estimated the proportion of women who would avoid a follow-up DXA after pulse-echo ultrasonometry, and the sensitivity and specificity of this for the detection of hip osteoporosis. Logistic regression models were used to estimate the associations of pulse-echo ultrasound measures with radiographically confirmed clinical fractures within the prior 5 years.

RESULTS:

Using multi-site and single-site DI measures, follow-up DXA could be avoided for 73 and 69 % of individuals, respectively, while detecting hip osteoporosis with 80-82 % sensitivity and 81 % specificity. Radiographically confirmed prior fracture was associated with ultrasound measures of single-site DI (odds ratio (OR) 1.55, 95 % confidence interval (CI). 1.06 to 2.26) and proximal tibia cortical thickness (OR 1.47, 95 % CI 1.10 to 1.96), adjusted for age, body mass index, and femoral neck BMD.

CONCLUSIONS:

Pulse-echo ultrasonometry can be used as an initial screening test for hip osteoporosis. Prospective studies of how well pulse-echo ultrasound measures predict subsequent clinical fractures are warranted.

2016-04-04·Medical physics3区 · 医学

Effect of porosity, tissue density, and mechanical properties on radial sound speed in human cortical bone

3区 · 医学

Article

作者: Töyräs, J ; Jurvelin, J S ; Malo, M K H ; Karjalainen, J P ; Eneh, C T M ; Liukkonen, J

PURPOSE:

The purpose of this study was to investigate the effect of simultaneous changes in cortical porosity, tissue mineral density, and elastic properties on radial speed of sound (SOS) in cortical bone. The authors applied quantitative pulse-echo (PE) ultrasound techniques that hold much potential especially for screening of osteoporosis at primary healthcare facilities. Currently, most PE measurements of cortical thickness, a well-known indicator of fracture risk, use a predefined estimate for SOS in bone to calculate thickness. Due to variation of cortical bone porosity, the use of a constant SOS value propagates to an unknown error in cortical thickness assessment by PE ultrasound.

METHODS:

The authors conducted 2.25 and 5.00 MHz focused PE ultrasound time of flight measurements on femoral diaphyses of 18 cadavers in vitro. Cortical porosities of the samples were determined using microcomputed tomography and related to SOS in the samples. Additionally, the effect of cortical bone porosity and mechanical properties of the calcified matrix on SOS was investigated using numerical finite difference time domain simulations.

RESULTS:

Both experimental measurements and simulations demonstrated significant negative correlation between radial SOS and cortical porosity (R(2) ≥ 0.493, p < 0.01 and R(2) ≥ 0.989, p < 0.01, respectively). When a constant SOS was assumed for cortical bone, the error due to variation of cortical bone porosity (4.9%-16.4%) was about 6% in the cortical thickness assessment in vitro.

CONCLUSIONS:

Use of a predefined, constant value for radial SOS in cortical bone, i.e., neglecting the effect of measured variation in cortical porosity, propagated to an error of 6% in cortical thickness. This error can be critical as characteristic cortical thinning of 1.10% ± 1.06% per yr decreases bending strength of the distal radius and results in increased fragility in postmenopausal women. Provided that the cortical porosity can be estimated in vivo, the relationship between radial SOS and cortical porosity can be utilized and a porosity based radial SOS estimate could be implemented to determine cortical thickness. This would constitute a step toward individualized quantitative ultrasound diagnostics of osteoporosis.

项与 Bone Index Finland Oy 相关的新闻（医药）

2024-08-20

·美通社

芬兰公司Bone Index完成新一轮融资并与德石资本达成战略合作

芬兰库奥皮奥 2024年8月20日 /美通社/ -- 总部位于芬兰的创新医疗技术公司Bone Index宣布完成新一轮融资。本轮融资由德石资本领投，其他欧洲投资方和现有股东跟投。公司同时宣布与德石资本建立战略合作伙伴关系，将Bone Index的创新技术及产品推向北美和亚太市场。 Bindex 本轮筹集的资金将用于帮助Bone Index提升生产能力和加速市场推广，以满足北美和亚太市场对其创新骨健康诊断产品日益增长的需求。Bone Index的核心技术在于快速和精准，是唯一同时适配早期筛查和院内检查两大场景的骨健康评估产品。公司产品已在欧洲和美国进行市场推广，实现了早期商业化。此次与德石资本的合作是Bone Index的重要战略决定，旨在扩大产品线以及为产品拓展新市场。 Bone Index创始人兼首席执行官Janne Karjalainen博士表示："本轮融资以及与德石资本的合作代表着我们成长旅程中的重要一步，这意味着我们有机会将我们最先进的骨骼健康诊断技术和骨质疏松诊断设备推向北美和亚太市场，带给更多受众，我们为此感到兴奋。" Bone Index董事会主席Tero Silvola补充道："我们很高兴与德石资本合作，他们在医疗健康领域内的专业知识、战略眼光和丰富经验，将为我们提供十分宝贵的帮助，支持我们扩大业务、加速发展以及实现未来愿景。" 德石资本管理合伙人许东表示："Bone Index是一家极具潜力的公司，他们的创新诊断技术拥有非常高的准确率和可及性，能够将骨质疏松早筛和诊断的形式变得更为简单、快速且人性化。我们相信Bone Index即将迎来显著增长，获得更多市场认可。我们也将全力支持Bone Index在亚太和全球市场实现其商业化愿景。" 关于 Bone Index 及其产品 Bindex ® 芬兰Bone Index Finland Oy，一家创新医疗设备公司，致力于研发和推广新一代骨健康筛查产品和技术。公司旗舰产品Bindex ®系统，一款突破性的即时诊断设备，1分钟即可得到精准快速的骨质疏松诊断，适合推广到更多院外场景，真正降低医疗负担。结合专利算法，Bindex ®可通过检测胫骨皮质骨厚度，实现对髋骨骨密度的准确预估。作为小巧的手持式设备，在多项临床试验中与金标准双能X线骨密度检查（DXA）的一致性高达90%，是一项能真正实现骨质疏松早期筛查和诊断的技术。德石资本 Lynx Financial 德石资本是一家专注于生命科学与医疗健康行业的投资机构。凭借国际化网络和落地中国本土的优势，德石资本充分利用其在项目研究、交易架构以及投融资方面的专业知识帮助其被投公司获得资金以及战略合作。更多信息请联系： Bone Index: Janne Karjalainen, CEO janne.karjalainen@boneindex.fi 德石资本: 洪逸梵，医疗健康研究员 rioh@lynx-financial.com

2024-08-20

·PRNewswire

Bone Index Announces Successful Financing Round and Strategic Partnership with Lynx Financial

KUOPIO, Finland, Aug. 20, 2024 /PRNewswire/ -- Bone Index Finland Ltd, a pioneering company in medical technology, proudly announces the completion of its latest financing round and a strategic partnership with Lynx Financial (HK) Limited. This partnership aims to enhance Bone Index's distribution and service capabilities in North America and Asia Pacific. The newly secured funds will bolster Bone Index's infrastructure and operations, meeting the growing demand for its innovative bone health diagnostics solutions in these key markets. The financing round, led by Lynx Financial, participated by other European financial investors and existing shareholders, highlights Bone Index's commitment to further product offerings and services. Bone Index core technology enables quick and accurate measurements of bone health, in both early screening and hospital settings. The company's product has achieved early commercialization and adoption in Europe and the US. The partnership with Lynx Financial is a major strategic decision for Bone Index as the company to expand its product line and market outreach. Statements from Leadership Janne Karjalainen, CEO of Bone Index, expressed his enthusiasm for the strategic partnership and financing round: "This investment and partnership with Lynx Financial are pivotal steps in our growth journey. The funds will significantly enhance our distribution and service capabilities in North America and Asia Pacific, allowing us to bring our state-of-the-art bone health diagnostics to a larger audience. We are excited about the opportunities this collaboration brings and are committed to delivering impactful health solutions globally." Tero Silvola, Chairman of the Board of Bone Index, added: "We are thrilled to have Lynx Financial join us as a partner. Their extensive experience in business development, particularly in the healthcare sector, will be invaluable as we expand our operations. Lynx's expertise and strategic insights will significantly accelerate our growth and help us achieve our vision. Donald Xu, Managing Director of Lynx Financial, commented: "We are excited about the potential of Bone Index's innovative diagnostics technology. Bone Index's solution is accurate and accessible and can democratize the way osteoporosis is detected and diagnosed for consumers and patients. We believe Bone Index is poised for significant growth and market penetration. We are committed to supporting Bone Index to achieve its visions, in Asia Pacific and globally. About Bone Index Bone Index Finland Oy is at the forefront of medical technology innovation, dedicated to developing and commercializing advanced bone health diagnostic solutions. The company's flagship product, the Bindex® system, is a revolutionary point-of-care device that provides accurate and rapid osteoporosis diagnostics. Bindex® measures the cortical bone thickness of the tibia, allowing for quick and reliable estimation of bone mineral density at the hip. This portable, pocket-sized device has a 90% accuracy rate, making it comparable to traditional DXA scans and enabling early diagnosis and treatment of osteoporosis. In addition, the technology has applications in various orthopedics treatment settings. The device's ease of use and immediate results significantly enhance patient care and reduce healthcare costs. Continue Reading Bindex (PRNewsfoto/BONE INDEX FINLAND) About Lynx Financial Lynx Financial is a boutique investment and investment banking firm that specializes in Life Sciences and Medical Technology sectors. With a global outreach and on-the-ground presence, Lynx Financial fully leverages its expertise in deal structuring and investments to help emerging innovative companies from around the world gain access to funding and strategic resources in Asia Pacific regions. For more information: Bone Index: Janne Karjalainen, CEO [email protected] +358 45 896 2650 Lynx Financial: Rio Hong, Associate [email protected] Photo - Logo - SOURCE BONE INDEX FINLAND